Discovery Analysis of TCGA Data Reveals Association between Germline Genotype and Survival in Ovarian Cancer Patients

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Braun, Rosemary ^a,b   Finney, Richard ^b   Yan, Chunhua ^b   Chen, Qing Rong ^b   Hu, Ying ^b   Edmonson, Michael ^b   Meerzaman, Daoud ^b   Buetow, Kenneth ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COPY NUMBER VARIATION; EXOME; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC VARIABILITY; GERM LINE; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

DISEASE-FREE SURVIVAL; EXOME; FEMALE; GENETIC LOCI; GENETIC MARKERS; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL RATE;

EID: 84875328119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055037     Document Type: Article

References (47)

1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, et al. (2011) SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute.
2. Blackledge G, Lawton F, Redman C, Kelly K, (1989) Response of patients in phase ii studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase ii trials. British Journal of Cancer 59: 650.
3. Huang R, Johnatty S, Gamazon E, Im H, Ziliak D, et al. (2011) Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clinical Cancer Research.
4. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, et al. (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104: 2807-2816.
5. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, et al. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
6. Han CH, Huang YJ, Lu KH, Liu Z, Mills GB, et al. (2011) Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. J Exp Clin Cancer Res 30: 5.
7. Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, et al. (2008) Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 14: 89-96.
8. Marsh S, Paul J, King C, Gifford G, McLeod H, et al. (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the scottish randomised trial in ovarian cancer. Journal of Clinical Oncology 25: 4528.
9. Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y, et al. (2012) Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility. Mol Cancer Ther 11: 2054-2061.
10. Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA, (2012) Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med 271: 366-378.
11. Nikas J, Boylan K, Skubitz A, Low W, (2011) Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Informatics 10: 233-47.
12. Hartmann L, Lu K, Linette G, Cliby W, Kalli K, et al. (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clinical Cancer Research 11: 2149.
13. Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, et al. (2012) Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS ONE 7: e30996.
14. TCGA (2011) The results published here are in whole or part based upon data generated by The Cancer Genome Atlas Pilot Project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov. (Data accessed 20 July 2011.).
15. Fasching P, Gayther S, Pearce L, Schildkraut J, Goode E, et al. (2009) Role of genetic polymorphisms and ovarian cancer susceptibility. Molecular Oncology 3: 171-181.
16. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, et al. (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42: 880-884.
17. Matsuo K, Bond V, Im D, Rosenshein N, (2010) Prediction of chemotherapy response with platinum and taxane in the advanced stage of ovarian and uterine carcinosarcoma: a clinical implication of in vitro drug resistance assay. American Journal of Clinical Oncology 33: 358.
18. Rose P, Tian C, Bookman M, (2010) Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A gynecologic oncology group study. Gynecologic Oncology 117: 324-329.
19. Nie Z, Hirsch DS, Randazzo PA, (2003) Arf and its many interactors. Curr Opin Cell Biol 15: 396-404.
20. Fernández-Ramires R, Solé X, De Cecco L, Llort G, Cazorla A, et al. (2009) Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of brca1 tumorigenesis. British Journal of Cancer 101: 1469-1480.
21. Arslan AA, Gold LI, Mittal K, Suen TC, Belitskaya-Levy I, et al. (2005) Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 20: 852-863.
22. Skubitz AP, Pambuccian SE, Argenta PA, Skubitz KM, (2006) Differential gene expression identifies subgroups of ovarian carcinoma. Transl Res 148: 223-248.
23. Sano H, Wada S, Eguchi H, Osaki A, Saeki T, et al. (2012) Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels. Breast Cancer 19: 37-45.
24. Hernandez-Vargas H, Rodriguez-Pinilla SM, Julian-Tendero M, Sanchez-Rovira P, Cuevas C, et al. (2007) Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 102: 157-172.
25. Prestayko A, d'Aoust J, Issell B, Crooke S, (1979) Cisplatin (cis-diamminedichloroplatinum II). Cancer Treatment Reviews 6: 17-39.
26. Jakupec M, Galanski M, Keppler B, (2003) Tumour-inhibiting platinum complexes-state of the art and future perspectives. Ergebnisse der Physiologie, Biologischen Chemie und Experimentellen Pharmakologie 146: 1-54.
27. Wang X, (2010) Fresh platinum complexes with promising antitumor activity. Anti-Cancer Agents in Medicinal Chemistry 10: 396-411.
28. Alderson K, Holds JB, Anderson RL, (1991) Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 41: 1800-1805.
29. Kang H, Kim I, Park J, Shin Y, Ku J, et al. (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clinical Cancer Research 10: 272.
30. Pazour G, Agrin N, Walker B, Witman G, (2006) Identification of predicted human outer dynein arm genes: candidates for primary ciliary dyskinesia genes. Journal of Medical Genetics 43: 62.
31. Chang H, Rha SY, Jeung HC, Jung JJ, Kim TS, et al. (2010) Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol 136: 1901-1913.
32. Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, et al. (2010) Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol 203: 1-40.
33. The International HapMap Consortium (2003) The International HapMap Project. Nature 426: 789-796.
34. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079.
35. R Development Core Team (2011) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0.
36. Therneau T, Lumley T (2011) survival: Survival analysis, including penalised likelihood. R package version 2.36-9.
37. Harrington D, Fleming T, (1982) A class of rank test procedures for censored survival data. Biometrika 69: 553.
38. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) pp. 289-300.
39. Johnson RC, Nelson GW, Troyer JL, Lautenberger JA, Kessing BD, et al. (2010) Accounting for multiple comparisons in a genome-wide association study (GWAS). BMC Genomics 11: 724.
40. Cantor R, Lange K, Sinsheimer J, (2010) Prioritizing gwas results: A review of statistical methods and recommendations for their application. The American Journal of Human Genetics 86: 6-22.
41. Han B, Kang H, Eskin E, (2009) Rapid and accurate multiple testing correction and power estimation for millions of correlated markers. PLoS Genetics 5: e1000456.
42. Aulchenko Y, Ripke S, Isaacs A, Van Duijn C (2007) GenABEL: an R library for genome-wide association analysis.
43. Fraley C, Raftery A, (2002) Model-based clustering, discriminant analysis, and density estimation. Journal of the American Statistical Association 97: 611-631.
44. Zhang J, Finney R, Rowe W, Edmonson M, Yang S, et al. (2007) Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). Genome research 17: 1111.
45. Wang K, Li M, Hakonarson H, (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Research 38: e164.
46. Clifford R, Edmonson M, Nguyen C, Buetow K, (2004) Large-scale analysis of non-synonymous coding region single nucleotide polymorphisms. Bioinformatics 20: 1006.
47. Ng P, Henikoff S, (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Research 31: 3812.